1-((5-methyl-2-(m-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxylic acid | 1119450-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-((5-methyl-2-(m-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxylic acid
• 英文别名: 1-{[5-Methyl-2-(3-methylphenyl)-1,3-oxazol-4-YL]-methyl}piperidine-4-carboxylic acid；1-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methyl]piperidine-4-carboxylic acid
• CAS: 1119450-03-1
• 化学式: C₁₈H₂₂N₂O₃
• mdl: MFCD12027168
• 分子量: 314.384
• InChiKey: VZNHZJAGUNBDBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-((5-methyl-2-(m-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxylic acid 、 N-甲基-N-甲氧基胺盐酸盐 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 生成 N-methoxy-N-methyl-1-((5-methyl-2-(m-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxamide
  参考文献：
  名称：

  [EN] COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
  [FR] COMPLEXES DE CUIVRE DESTINÉS AU TRAITEMENT D'ÉTATS NEURODÉGÉNÉRATIFS

  摘要：

  本公开涉及铜配合物、包含这些配合物的药物组合物、制备这些配合物的化学过程，以及它们在治疗神经退行性疾病（例如肌萎缩侧索硬化症）中的应用。

  公开号：

  WO2022047014A1
• 作为产物：
  描述：

  4,5-dimethyl-2-(m-tolyl)oxazole 3-oxide 在 potassium hydroxide 、 三氯氧磷 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 16.5h， 生成 1-((5-methyl-2-(m-tolyl)oxazol-4-yl)methyl)piperidine-4-carboxylic acid
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561

文献信息

• Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle
  作者：Shanshan He、Kelin Li、Billy Lin、Zongyi Hu、Jingbo Xiao、Xin Hu、Amy Q. Wang、Xin Xu、Marc Ferrer、Noel Southall、Wei Zheng、Jeffrey Aubé、Frank J. Schoenen、Juan J. Marugan、T. Jake Liang、Kevin J. Frankowski

  DOI：10.1021/acs.jmedchem.7b00561

  日期：2017.7.27

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.
• [EN] COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPLEXES DE CUIVRE DESTINÉS AU TRAITEMENT D'ÉTATS NEURODÉGÉNÉRATIFS
  申请人：ALS THERAPY DEVELOPMENT INST

  公开号：WO2022047014A1

  公开（公告）日：2022-03-03

  The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

  本公开涉及铜配合物、包含这些配合物的药物组合物、制备这些配合物的化学过程，以及它们在治疗神经退行性疾病（例如肌萎缩侧索硬化症）中的应用。